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Abstract
Background: Non-small cell lung cancer (NSCLC) represents the majority (85%) of lung cancers and is comprised mainly of
adenocarcinomas and squamous cell carcinomas (SCCs). The sequential pathogenesis of lung adenocarcinomas and SCCs
occurs through dissimilar phases as the former tumors typically arise in the lung periphery whereas the latter normally arise
near the central airway.
Methodology/Principal Findings: We assessed the expression of SOX2, an embryonic stem cell transcriptional factor thatalso
plays important roles in the proliferation of basal tracheal cells and whose expression is restricted to the main and central
airways and bronchioles of the developing and adult mouse lung, in NSCLC by various methodologies. Here, we found that
SOX2 mRNA levels, from various published datasets, were significantly elevated in lung SCCs compared to adenocarcinomas
(all p,0.001). Moreover, a previously characterized OCT4/SOX2/NANOG signature effectively separated lung SCCs from
adenocarcinomas in two independent publicly available datasets which correlated with increased SOX2 mRNA in SCCs.
Immunohistochemical analysis of various histological lung tissue specimens demonstrated marked nuclear SOX2 protein
expression in all normal bronchial epithelia, alveolar bronchiolization structures and premalignant lesions in SCC development
(hyperplasia, dysplasia and carcinoma in situ) and absence of expression in all normal alveoli and atypical adenomatous
hyperplasias. Moreover, SOX2 protein expression was greatly higher in lung SCCs compared to adenocarcinomas following
analyses in two independent large TMA sets (TMA set I, n=287; TMA set II, n=511 both p,0.001). Furthermore, amplification
of SOX2 DNA was detected in 20% of lung SCCs tested (n=40) and in none of the adenocarcinomas (n=17).
Conclusions/Significance: Our findings highlight a cell-lineage gene expression pattern for the stem cell transcriptional
factor SOX2 in the pathogenesis of lung SCCs and suggest a differential activation of stem cell-related pathways between
squamous cell carcinomas and adenocarcinomas of the lung.
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Introduction
Lung cancer continues to be the leading cause of cancer-related
deaths in the United States and worldwide with over one million
deaths each year [1]. The majority of lung cancers (85%) are
NSCLCs that include SCCs and adenocarcinomas [2]. The
pathogenesis of NSCLC involves the accumulation of genetic and
epigenetic alterations in a long multi-step process due in part to
chronic exposure to carcinogens such as tobacco smoke. Few early
changes that occur during NSCLC pathogenesis have been
identified. For example, mutations in KRAS [3] and in the
epidermal growth factor receptor (EGFR) [4] typically occur early
in the development of lung adenocarcinomas, whereas amplifica-
tion of EGFR and PI3KCA [2] and epigenetic inactivation of the
p16 tumor suppressor [5] are more frequent in SCC pathogenesis
relative to adenocarcinomas. Moreover, the developmental
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9112transcription factor Thyroid transcriptional factor 1 (TITF1) has
been shown to be a lineage-survival oncogene over-expressed and
amplified in lung adenocarcinoma development [6]. Despite
recent progress in the delineation of cellular pathways aberrantly
modulated in NSCLC, our understanding of the molecular
changes occurring early in NSCLC pathogenesis is still lacking.
Given that the embryonic stem cell SOX2 transcriptional factor
[7] plays important roles in tracheal epithelial cells [8] and is only
expressed in the main airways and non-branching bronchioles in
the developing and adult mouse lung [9], we hypothesized that it
may be a cell-lineage gene highly and specifically expressed in
SCCs that originate from central and upper airway and bronchial
epithelial cells relative to adenocarcinomas that typically arise
from the lung periphery [10]. In this study, we found that SOX2
mRNA was largely higher in lung SCCs relative to adenocarci-
nomas from various microarray datasets. Moreover, when we
analyzed an OCT4/SOX2/NANOG stem cell gene signature
previously characterized by Boyer et al. [11] in independent
publicly available NSCLC datasets, the signature was found to
effectively discriminate both major NSCLC subtypes. In addition,
we found marked SOX2 protein expression only in the
pathogenesis of SCC which was greatly higher in SCCs relative
to lung adenocarcinomas following analyses of two independent
and large tissue microarray (TMA) sets. Lastly, amplification of
SOX2 DNA assessed by quantitative PCR (qPCR) was evident in
20% of lung SCCs studied (n=40) and was absent in all
adenocarcinoma cases tested (n=17).
Results
Elevated Expression of SOX2 mRNA in Lung SCCs Relative
to Adenocarcinomas in Various Microarray Datasets
Analysis of SOX2 mRNA expression in NSCLC samples of
various publicly available datasets revealed the significant elevated
expression of this stem cell-related transcriptional factor in lung
SCCs compared to adenocarcinomas (all p,0.001) (Figure 1A).
This differential expression pattern was also evident when
microarray analysis was performed on FFPE tissue sections of
NSCLC (p,0.001) (Figure S1).
A Previously Characterized OCT4/SOX2/NANOG Signature
Effectively Discriminates Lung SCCs from Adenocarcinomas
Since SOX2 mRNA levels were largely higher in SCCs than
adenocarcinomas of the lung, we questioned whether a SOX2-
Figure 1. Increased expression of SOX2 mRNA in lung SCCs relative to adenocarcinomas. A. Normalized centered SOX2 mRNA expression
levels downloaded from four published microarray data sets as described in the Methods. The lead author of each published microarray cohort data
is indicated in each panel. The number of analyzed samples is indicated below each column bar. p-values represent statistical significance assessed by
independent two-sided t-tests. B. Hierarchical cluster analysis with average linkage of the expression of the previously characterized OCT4/SOX2/
NANOG signature [11] using present probe sets features in the array platforms of the datasets by Bhattacharjee et al. [12] (B), and Bild et al. [13] (C).
Data are represented in a matrix format in which individual rows represent single gene features and columns represent experiments. High or low
gene expression levels are indicated by red or green color, respectively as indicated by the log2 transformed scale bars. D. Principal component
analysis of the signature in the Bild et al. dataset using metric centered correlation.
doi:10.1371/journal.pone.0009112.g001
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NSCLC. Using only gene features represented in the published
dataset platforms, the previously characterized OCT4/SOX2/
NANOG signature by Boyer et al. [11] was analyzed alone using
human gene expression data from the studies by Bhattacharjee
et al and Bild et al [12,13]. In both datasets, the OCT4/SOX2/
NANOG signature effectively separated lung tumors based on
histology where most SCCs clustered alone (Figures 1B and 1C).
In hierarchical cluster analysis of the Bild dataset, 43 out of 53
SCCs clustered together (Figure 1C) (p=4.3610
210 of the x-test).
The sensitivity and specificity for the classification of SCCs and
lung adenocarcinomas were 0.81 and 0.78, respectively (Table
S1). Moreover, the separation of SCCs from lung adenocarcino-
mas by the signature was also evident by principal component
analysis in three-dimensional space (Figure 1D). In addition,
SOX2 expression in the cluster analyses was higher in lung SCCs
relative to adenocarcinomas. Moreover, the expression of SOX2
mRNA correlated with that of genes such as fibroblast growth
factor receptor 2 (FGFR2) and parathyroid hormone-like
hormone (pTHLH) in cluster analyses of both independent
datasets (Figures 1B and 1C). In an attempt to validate these
findings, we correlated the protein expression of SOX2 with that
of FGFR2 by TMA immunohistochemistry analysis and found
that nuclear SOX2 protein levels correlated significantly with
cytoplasmic FGFR2 levels in lung SCC histological tissue
specimens (Figure S2) but not in adenocarcinomas (data not
shown).
Differential Expression of SOX2 Protein between Lung
Adenocarcinoma and SCC Development Phases As
Revealed by Immunohistochemical Analyses
We next attempted to analyze SOX2 expression at the protein
level in histological tissue specimens representing different stages in
the pathogenesis of lung adenocarcinomas and SCCs. Strikingly,
SOX2 protein expression was absent in all normal alveoli (n=52)
and AAH (n=37) (Figure 2 and Table 1). In sharp contrast, SOX2
positive expression was mainly nuclear and evident in all normal
bronchial epithelia (n=52), all four alveolar bronchiolization
structures and in all (n=32) but one cases of dysplasia and
carcinoma in situ representing the sequence of SCC pathogenesis
(Figure 2 and Table 1).
Elevated Expression of SOX2 DNA and Protein in Lung
SCCs Relative to Adenocarcinomas
We next sought to analyze SOX2 protein expression in NSCLC
tissue microarrays. The characteristics of the NSCLC patients from
which the tissue specimens were obtained are summarized in Table
S2. Nuclear SOX2 levels were largely and statistically significantly
higher in lung SCCs (n=109, set I; n=177 set II) relative to the
levels in adenocarcinomas (set I, n=178; set II, n=334) (both
p,0.001) (Figure 3A). Notably, the median level of SOX2 protein
was 8.2 and 39.7 higher in lung SCCs relative to adenocarcinomas
when analyzed in TMA sets I and II, respectively (set I,
adenocarcinoma, 30, SCC, 245; set II, adenocarcinoma 5.8,
Figure 2. SOX2 protein is highly expressed in the pathogenesis of lung SCC but not of adenocarcinoma. A. Representative
photomicrographs displaying the immunohistochemical expression of SOX2 protein in histological tissue sections of normal bronchial
epithelia, preneoplastic lesions representing SCC development (Hyperplasia, Dysplasia and carcinoma in situ), and in well (Well SCC) and
poorly (Poor SCC) differentiated SCCs. B. Representative photomicrographs of SOX2 expression in lung parenchyma (LP), atypical
adenomatous hyperplasia (AAH), alveolar bronchiolization structures (AB), and in acinar adenocarcinoma and bronchioalveolar carcinoma
(BAC).
doi:10.1371/journal.pone.0009112.g002
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protein expression was statistically significantly higher in ever
compared to never smokers (set I, p=0.002; set II, p,0.001)
(Figure 3B) and was also significantly increased in current or former
smokers compared to never smoker NSCLC patients (set I,
p=0.008; set II, p,0.001) (Figure 3C). Furthermore, in analysis
of both TMA sets, SOX2 protein expression was comparable
between former and current smoker NSCLC patients.
We also assessed for the levels of SOX2 DNA copy number in 57
NSCLC tumors. We found 20% SCCs had gene copy gain (8/40;
6/29 with high SOX2 protein expression and 2/11 with low
SOX2 expression) (Table S3). In contrast, none of the 17
adenocarcinomas tested displayed SOX2 gene copy gain with
most cases (83%) exhibiting SOX2 DNA RQs,1.
Discussion
In this study, we sought to investigate the expression patterns of
SOX2 in NSCLC pathogenesis based on its role and function in the
developing and adult mouse lung and trachea [8,9]. We found that
SOX2 mRNA levels are significantly higher in lung SCCs relative
to adenocarcinomas or large-cell lung carcinomas from various
published microarray datasets. Moreover, a previously character-
ized OCT4/SOX2/NANOG embryonic stem cell expression
signature [11] effectively separated SCCs from lung adenocarci-
nomas when analyzed in publicly available NSCLC microarray
datasets. In addition, we found that SOX2 protein was completely
absent in lung adenocarcinoma pathogenesis and highly expressed
in SCC development. Lastly, we demonstrated that SOX2 protein
expression was largely significantly elevated in lung SCCs relative
Figure 3. Increased SOX2 expression in lung SCCs compared to adenocarcinomas and its association with smoking patterns. Box-
plot depicting statistical analysis by the Wilcoxon-rank test of differences in nuclear SOX2 protein score in both TMA sets I and II between lung
adenocarcinomas (ADC) and SCCs (A), ever and never NSCLC smokers (B) and between never, former and current smokers (C).
doi:10.1371/journal.pone.0009112.g003
Table 1. SOX2 expression in normal and preneoplastic lung
lesions.
Tissue type N
Immunohistochemistry
Expression
Positive Negative
Normal bronchial epithelia 52 52 0
Normal alveoli 52 0 52
Atypical adenomatous
hyperplasia (AAH)
37 0 37
Alveolar bronchiolization 44 0
Squamous dysplasia and
carcinoma in situ
32 31 1
doi:10.1371/journal.pone.0009112.t001
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sets and copy gain of the gene was evident in 20% of lung SCCs
studied and absent in adenocarcinomas. These findings entail the
possible clinical application of SOX2 expression as a diagnostic
biomarker to discriminate lung SCCs from adenocarcinomas, in
an analogous fashion to the potential application of TITF1 as a
biomarker for lung adenocarcinomas but not SCCs [2,6].
It is noteworthy that the OCT4/SOX2/NANOG signature is
comprised of genes under direct transcriptional control by the
SOX2 transactivating factor [11]. Given the effective separation of
lung SCCs and adenocarcinomas by this signature, it is possible
that other genes directly or indirectly related to SOX2 signaling are
also dissimilar in expression between both NSCLC subtypes. In
accordance and based on analysis of the expression signature in
two independent microarray datasets, we validated and demon-
strated the correlative expression of both SOX2 and FGFR2
protein in lung SCC tissue histological specimens. Interestingly,
FGFR2 has been shown to be critical for the formation of the lung
bud, which typically is associated with SOX2 expression and TITF-
1 repression, and mice lacking this gene do not form lungs
[9,14,15]. It is plausible to suggest that the reduction in SOX2
expression in adenocarcinomas of the lung may be evolutionarily
conserved.
While completing our study, Bass et al reported an amplification
of SOX2 in esophageal (15%) and lung SCCs (23%) [16] assessed
by Affymetrix single nucleotide polymorphism (SNP) arrays.
Similarly, we found copy gain of the SOX2 gene in 20% of lung
SCCs as revealed by our quantitative PCR analysis. Notably, we
also analyzed a set of lung adenocarcinomas and found no
significant SOX2 copy number gain further demonstrating a cell-
lineage expression pattern for SOX2 specifically in lung SCCs. In
contrast to the study by Bass et al, we also assessed SOX2 protein
levels in lung SCCs and adenocarcinomas using two independent
and large tissue microarrays and correlated the expression of
SOX2 protein expression and copy number gain in 57 NSCLC
samples. It is note worthy that several cases displayed discordant
SOX2 protein and copy number gain. It is reasonable to suggest
that SOX2 expression may be regulated at different levels; at the
DNA, mRNA and protein and that it may be important to assess
for its expression at all three levels.
In conclusion, we demonstrated a vast increase in expression of
the pluripotent stem cell related transcriptional factor, SOX2,i n
squamous cell carcinomas relative to adenocarcinomas of the lung.
Moreover, our findings raise the possibility of the activation of
SOX2-dependent stem cell-related pathways in squamous cell
carcinomas of the lung.
Materials and Methods
Analysis of SOX2 mRNA in Published Microarray Datasets
and Integration of the OCT4/SOX2/NANOG Signature
The integrated cancer microarray database and data-mining
platform, Oncomine [17], was utilized to analyze the expression of
SOX2 in publicly available microarray datasets of human lung
carcinomas available on-line. SOX2 mRNA (probe sets 213721_at
and 228038_at) was also compared by microarray analysis
between formalin-fixed paraffin embedded (FFPE) lung SCCs
and adenocarcinomas (unpublished observations). Genes charac-
terizing an OCT4/SOX2/NANOG expression signature [11] were
compiled and queried using NetAffx
TM from Affymetrix (http://
www.affymetrix.com/analysis/index.affx) to search for corre-
sponding probe set annotations in the HG-U95A and HG-U133
plus 2.0 platforms used in the lung cancer microarray studies by
Bhattacharjee et al. [12] and Bild et al. [13], respectively. The
OCT4/SOX2/NANOG signature gene features were then analyzed
alone in published human gene expression data obtained from the
reports by Bhattacharjee et al. and Bild et al. Raw microarray data
files from the two published datasets were imported and analyzed
using the BRB-ArrayTools v.3.7.0 developed by Dr. Richard
Simon and BRB-ArrayTools Development Team [18]. Gene
expression data were normalized by Robust multi-array analysis
(RMA) in R language environment [19] and median-centered
across all samples in each data set before hierarchical clustering
analysis. Clustering by average linkage was performed with Cluster
2.11, and results were visualized with TreeView programs
(Michael Eisen Laboratory, Lawrence Berkeley National Labora-
tory and University of California, Berkeley; http://rana.lbl.gov/
EisenSoftware.htm). Principal component analysis following gene
centering was performed using the BRB-ArrayTools software.
Immunohistochemistry Analysis, Human Lung Tissues
and Tissue Microarray Sets I and II
Detailed description of the normal and preneoplastic histological
tissuespecimensanalyzed and twoTMAsetsisavailableinMethods
S1. Cytoplasmic FGFR2 protein expression was available based on
previous analysis [20]. Details of the immunohistochemical analysis
for SOX2 protein expression are also available in Methods S1.
DNA Extraction and Quantitative PCR (qPCR)
Tumor tissues (40 SCCs, 17 adenocarcinomas) were dissected
from FFPE Hematoxylin-stained tissue sections using manual
microdissection to ensure that tumor cell proportions are greater
than 70% for subsequent DNA extraction. Tumor DNA was
extracted using the PicoPure DNA extraction Kit (Arcturus, Mt
View, CA) according to the manufacturer’s instructions. Five mlo f
DNA was added to a 20 ml final volume reaction mixture consisting
of 10 ml Power SYBRH Green PCR Master Mix (Applied
Biosystems, Foster City, CA) and 0.5 mmol/l of each of forward
and reverse primers which span 102 dinucleotides (613 to 714) of
the SOX2 gene (ID: NM 003106) as follows: 59- GAACCCCAA-
GATGCACAACTC and 59-CGCTTAGCCTCGTCGATGA-
AC. b-actin was used as an endogenous reference gene (TaqManH
Control Human Genomic DNA, Applied Biosystems) and was
amplified as a standard control for calibration. All samples and
standard DNA reactions were carried out in triplicates. qPCR was
performed using an ABI 7300 Real Time PCR System Sequence
(Applied Biosystems) at 50uC for 2 min, 95uC for 10 min, followed
by 40 cycles at 95uC for 15 s and 60uC for 1 min. The quantity of
the target genes were normalized using the level of the b-actin gene,
and expressed as relative quantities (RQ) compared with the value
of the Human Genomic DNA. RQ equal or larger than 2 was
considered as gene copy gain.
Statistical Analyses
The data were summarized using standard descriptive statistics.
The rank-based non-parametric Wilcoxon rank-sum test and the
Kruskal-Wallis test were used to assess the statistical significance of
the differences in nuclear SOX2 staining intensity score between
lung SCCs and adenocarcinomas and based on tobacco history
(ever vs never smokers) and type of smokers (never vs former vs
current). All tests were two sided. p-values ,0.05 were considered
statistically significant.
Supporting Information
Methods S1 Supplementary methods.
Found at: doi:10.1371/journal.pone.0009112.s001 (0.04 MB
DOC)
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relative to adenocarcinomas in FFPE NSCLC specimens. SOX2
levels were analyzed from microarray analysis of FFPE NSCLC
specimens using the Affymetrix HG-U133A platform. P-values
were obtained by the Student’s t-test.
Found at: doi:10.1371/journal.pone.0009112.s002 (0.22 MB TIF)
Figure S2 Correlation of expression of SOX2 and FGFR2
protein in lung SCC tissue specimens. SOX2 and FGFR2 protein
levels were assessed by immunohistochemistry as described in
Methods S1. Assessment of significance in correlation between
SOX2 nuclear and FGFR2 cytoplasmic protein levels was
performed using the Spearman Rank correlation test.
Found at: doi:10.1371/journal.pone.0009112.s003 (0.31 MB TIF)
Table S1 Separation of 111 NSCLCs from the study of Bild
et al. by the OCT4/SOX2/NANOG signature. *P-value was
obtained by Fisher’s exact test. Sensitivity (probability for an SCC
sample to be correctly predicted as SCC)=0.811. Specificity
(probability for an ADC sample to be correctly predicted as an
ADC)=0.776.
Found at: doi:10.1371/journal.pone.0009112.s004 (0.03 MB
DOC)
Table S2 Patient characteristics in tissue microarray sets I and
II.
Found at: doi:10.1371/journal.pone.0009112.s005 (0.05 MB
DOC)
Table S3 Analysis of SOX2 gene copy gain in lung SCCs and
adenocarcinomas and its correlation with its corresponding
protein levels. CN, SOX2 gene copy number assessed as relative
quantities (RQs) to b-actin.
Found at: doi:10.1371/journal.pone.0009112.s006 (0.03 MB
DOC)
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